Despite its utility, the Sakitamiwa Classification is not without critics. Key limitations include:
The next iteration—Sakitamiwa 4.0 (expected 2026)—aims to incorporate liquid biopsy biomarkers (circulating tumor DNA, exosomal microRNAs) and artificial intelligence-driven whole-slide image analysis. Preliminary data suggest that AI-enhanced Sakitamiwa grading achieves 94% concordance with expert consensus, compared to 78% for human-only grading. sakitamiwa classification
A prospective cohort of 1,204 patients (2021–2023) demonstrated the classification’s predictive power: Despite its utility, the Sakitamiwa Classification is not
| Stage | n (%) | 14-day mortality | Progression to higher stage | Likelihood of severe bleeding | |-------|-------|------------------|-----------------------------|-------------------------------| | 0 | 310 (25.8%) | 0.0% | 2.3% | 0% | | I | 487 (40.4%) | 1.2% | 8.7% | 0.4% | | II | 255 (21.2%) | 8.6% | 21.2% | 5.1% | | III | 112 (9.3%) | 41.1% | 33.0% | 38.4% | | IV | 40 (3.3%) | 72.5% | N/A | 67.5% | A prospective cohort of 1
Patients staged within 48 hours of fever onset who receive stage-appropriate therapy (e.g., early ribavirin for Stage I; plasma exchange for Stage III) have a 54% relative risk reduction in progression to Stage IV (NNT = 6). Importantly, the Classification also identifies a subset of Stage III with hyperferritinemia (> 5,000 ng/mL) – termed "Sakitamiwa Macrophage Activation Syndrome" – which responds to anakinra (IL-1 blockade) but not corticosteroids.